- Conditions
- Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture), Rupture of Membranes; Premature, Rupture of Membranes; Premature, Affecting Fetus, Preterm Birth, Preterm PROM (Pregnancy), Preterm Labor
- Interventions
- Antibiotics, oral Azithromycin and oral Amoxicillin
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 173
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Premature Birth of Newborn, Enterocolitis, Necrotizing
- Interventions
- Ampicillin, Gentamicins, Placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- Up to 6 Hours
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cat Bite, Hand Injuries, Arm Injury, Infection, Bacterial, Anti-bacterial Agents
- Interventions
- Amoxicillin/clavulanate, Ciprofloxacin, Clindamycin, Placebo (microcrystalline cellulose), Wound management
- Drug · Other · Procedure
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Positive E Coli Infections
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Penicillin Allergy
- Interventions
- Amoxicillin
- Drug
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Danville, Pennsylvania • Lewiston, Pennsylvania • Scranton, Pennsylvania + 1 more
- Conditions
- Tonsillitis
- Interventions
- amoxicillin, azithromycin SR
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 693 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 33
- States / cities
- Hoover, Alabama • Pelham, Alabama • Fresno, California + 20 more
- Conditions
- Intra Abdominal Infections
- Interventions
- Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem
- Drug
- Lead sponsor
- Iterum Therapeutics, International Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more
- Conditions
- Healthy
- Interventions
- Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
- Drug
- Lead sponsor
- Ranbaxy Laboratories Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Acute Otitis Media (AOM)
- Interventions
- Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 6 Months to 36 Months
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
- Conditions
- E Coli Infection, ESBL Producing E.Coli
- Interventions
- Cefotetan, Carbapenems, Beta Lactam Antibiotics
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pancreatic Fistula
- Interventions
- Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
- Interventions
- Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Not listed
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Sinusitis, Respiratory Tract Infections
- Interventions
- Amoxicillin-clavulanate, Placebo
- Drug
- Lead sponsor
- Nader Shaikh
- Other
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Bardstown, Kentucky • Gresham, Oregon • Philadelphia, Pennsylvania + 3 more
- Conditions
- Cystic Fibrosis, Chronic Bronchitis
- Interventions
- IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
- Conditions
- Vaginitis Gardnerella
- Interventions
- Amoxicillin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Winston-Salem, North Carolina
- Conditions
- Antibiotic-associated Diarrhea
- Interventions
- Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, BB-12, Control
- Drug · Biological · Other
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
- Interventions
- Supportive Care + Amoxicillin, Supportive Care + Placebo (no antibiotics)
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Months to 71 Months
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Tonsillectomy
- Interventions
- 7 days of amoxicillin, 3 days of amoxcillin followed by 4 days of placebo
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis
- Interventions
- Meropenem-Vaborbactam, Piperacillin-Tazobactam, Levofloxacin, Saline
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 8
- States / cities
- Mobile, Alabama • San Diego, California • Denver, Colorado + 5 more
- Conditions
- Periodontitis
- Interventions
- scaling and root planing, local tetracycline, systemic metronidazole and amoxicillin, surgery, local antibiotics and systemic metronidazole and amoxicillin, local tetracycline and periodontal surgery, periodontal surgery and systemic metronidazole and amoxicillin, surgery, local tetracycline, systemic metronidazole and amoxicillin
- Other · Drug
- Lead sponsor
- The Forsyth Institute
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Complicated Urinary Tract Infections or Pyelonephritis
- Interventions
- Doripenem, Doripenem placebo, Cefepime, Cefepime placebo, Amoxicillin/clavulanate potassium
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Oakland, California • Orange, California + 8 more
- Conditions
- Hematologic Neoplasms
- Interventions
- Piperacillin/Tazobactam (Tazocin)
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
- Conditions
- Premature Birth, Antibiotics, Neurodevelopment
- Interventions
- Ampicillin, Gentamicin, Placebo
- Drug
- Lead sponsor
- Sharp HealthCare
- Other
- Eligibility
- 23 Weeks to 30 Weeks
- Enrollment
- 802 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 14
- States / cities
- San Diego, California • New Haven, Connecticut • Tampa, Florida + 9 more